Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Sabarinath Venniyil Radhakrishnan MD

Sabarinath Venniyil Radhakrishnan MD profile photo picture

Assistant Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Hematology

Member of the Cancer Center
Member of the Center for Immunology

View Curriculum Vitae

Publications (30)

  • Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients. (Chunara F, Lugo C, Osinski K, Shah MR, Shah N, Kent J, Mohyuddin GR, Radhakrishnan SV, Kaur G, Chakraborty R, Banerjee R, Rasche L, Schinke C, D'Souza A, Szabo A, Mohan M) Blood Cancer J 2025 Apr 08;15(1):61 PMID: 40199861 PMCID: PMC11979001 SCOPUS ID: 2-s2.0-105003231303 04/09/2025       4 Citations
  • Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study. (Gong Z, Umoru G, Monge J, Shah N, Mohyuddin GR, Radhakrishnan SV, Chakraborty R, Rasche L, Schinke C, D'Souza A, Mohan M) Blood Cancer J 2024 Mar 05;14(1):36 PMID: 38443341 PMCID: PMC10914796 SCOPUS ID: 2-s2.0-85186936720 03/06/2024       13 Citations
  • Restricting CAR T Cell Trafficking Expands Targetable Antigen Space. (Morales EA, Dietze KA, Baker JM, Wang A, Avila SV, Iglesias F, Radhakrishnan SV, Mause EV, Olson ML, Sun W, Rosati E, Chidester SL, Iraguha T, Fan X, Atanackovic D, Luetkens T) bioRxiv 2024 Feb 11 PMID: 38370665 PMCID: PMC10871312 02/19/2024    
  • Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. (Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, Rein LE, Janardan A, Bhatlapenumarthi V, Annyapu E, Skoog C, Goff A, Hadidi SA, Radhakrishnan SV, Thanendrarajan S, Zangari M, Shah N, van Rhee F, Dhakal B, Hamadani M, D'Souza A, Schinke C) Bone Marrow Transplant 2024 May;59(5):647-652 PMID: 38361116 SCOPUS ID: 2-s2.0-85185115608 02/16/2024       17 Citations
  • Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. (Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah NN, Hamadani M, D'Souza A, Hari P, Dhakal B) Br J Haematol 2024 Mar;204(3):887-891 PMID: 38054558 SCOPUS ID: 2-s2.0-85178904872 12/06/2023       5 Citations
  • Blood and marrow transplant within 4 weeks of SARS-CoV-2 infection is associated with increased risk of mortality: a National COVID Cohort Collaborative (N3C) Study. (Mohan M, Kothari A, Verhagen N, Shreenivas A, Radhakrishnan SV, Dhakal B, Figueroa-Castro C, Chhabra S, Janz S, Pasquini M, Hamadani M, Szabo A, D'Souza A, N3C consortium) Bone Marrow Transplant 2024 Jan;59(1):121-124 PMID: 37803198 SCOPUS ID: 2-s2.0-85173730029 10/07/2023       2 Citations
  • The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. (Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C) Haematologica 2024 Mar 01;109(3):906-914 PMID: 37646658 PMCID: PMC10905074 SCOPUS ID: 2-s2.0-85178101970 08/30/2023       39 Citations
  • Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity. (Vander Mause ER, Baker JM, Dietze KA, Radhakrishnan SV, Iraguha T, Omili D, Davis P, Chidester SL, Modzelewska K, Panse J, Marvin JE, Olson ML, Steinbach M, Ng DP, Lim CS, Atanackovic D, Luetkens T) Sci Transl Med 2023 Jul 19;15(705):eadd7900 PMID: 37467316 SCOPUS ID: 2-s2.0-85165317486 07/19/2023       23 Citations
  • Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. (Al Hadidi S, Szabo A, Esselmann J, Hammons L, Hussain M, Ogunsesan Y, Thalambedu N, Khan F, Sethi J, Janardan A, Radhakrishnan SV, Thanendrarajan S, Schinke C, Dhakal B, Janz S, Chhabra S, D'Souza A, Zangari M, van Rhee F, Mohan M) Bone Marrow Transplant 2023 Apr;58(4):443-445 PMID: 36550200 SCOPUS ID: 2-s2.0-85144572498 12/23/2022       20 Citations
  • Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. (Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Price M, Shirey M, Warner D, Thanendrarajan S, Janz S, Radhakrishnan SV, Al Hadidi S, Szabo A, D'Souza A, Zangari M, van Rhee F, Chhabra S, Schinke C) Am J Hematol 2022 Dec;97(12):E451-E453 PMID: 36097868 SCOPUS ID: 2-s2.0-85139019826 09/14/2022       13 Citations
  • Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion (Olson ML, Mause ERV, Radhakrishnan SV, Brody JD, Rapoport AP, Welm AL, Atanackovic D, Luetkens T) Leukemia July 2022;36(7):1943-1946 SCOPUS ID: 2-s2.0-85129213162 07/01/2022       83 Citations
  • Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion. (Olson ML, Mause ERV, Radhakrishnan SV, Brody JD, Rapoport AP, Welm AL, Atanackovic D, Luetkens T) Leukemia 2022 Jul;36(7):1943-1946 PMID: 35490197 PMCID: PMC9252916 SCOPUS ID: 2-s2.0-85129213162 05/01/2022       82 Citations
  • Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. (Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C) Am J Hematol 2022 Jul;97(7):E276-E280 PMID: 35472167 PMCID: PMC10476149 SCOPUS ID: 2-s2.0-85129190892 04/27/2022       5 Citations
  • Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. (Mohan M, Nagavally S, Dhakal B, Radhakrishnan SV, Chhabra S, D'Souza A, Hari P) Blood Adv 2022 Apr 26;6(8):2466-2470 PMID: 34933344 PMCID: PMC9043928 SCOPUS ID: 2-s2.0-85129331026 12/22/2021       51 Citations
  • The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases Early Gastrointestinal GVHD in Experimental Allogeneic Hematopoietic Cell Transplantation. (Palaniyandi S, Kumari R, Venniyil Radhakrishnan S, Strattan E, Hakim N, Munker R, Kesler MV, Hildebrandt GC) Transplantation 2020 Dec;104(12):2507-2515 PMID: 32639407 PMCID: PMC8139022 SCOPUS ID: 2-s2.0-85096509107 07/09/2020       7 Citations
  • CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. (Radhakrishnan SV, Luetkens T, Scherer SD, Davis P, Vander Mause ER, Olson ML, Yousef S, Panse J, Abdiche Y, Li KD, Miles RR, Matsui W, Welm AL, Atanackovic D) Nat Commun 2020 Feb 07;11(1):798 PMID: 32034142 PMCID: PMC7005855 SCOPUS ID: 2-s2.0-85079080842 02/09/2020       66 Citations
  • A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma. (Radhakrishnan SV, Boyer M, Sherwin CM, Zangari M, Tricot G) Cell Transplant 2019 Dec;28(12):1624-1631 PMID: 31619057 PMCID: PMC6923548 SCOPUS ID: 2-s2.0-85076876281 10/18/2019       1 Citation
  • In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. (Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Kröger N, Luetkens T) Leukemia 2020 Jan;34(1):317-321 PMID: 31409922 SCOPUS ID: 2-s2.0-85070798814 08/15/2019       31 Citations
  • The role of surface molecule CD229 in Multiple Myeloma. (Olson M, Radhakrishnan SV, Luetkens T, Atanackovic D) Clin Immunol 2019 Jul;204:69-73 PMID: 30326256 SCOPUS ID: 2-s2.0-85055712528 10/17/2018       16 Citations
  • Novel anti-myeloma immunotherapies targeting the SLAM family of receptors. (Radhakrishnan SV, Bhardwaj N, Luetkens T, Atanackovic D) Oncoimmunology 2017;6(5):e1308618 PMID: 28638731 PMCID: PMC5468000 SCOPUS ID: 2-s2.0-85019019970 06/24/2017       22 Citations
  • Elotuzumab as a novel anti-myeloma immunotherapy. (Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D) Hum Vaccin Immunother 2017 Aug 03;13(8):1751-1757 PMID: 28604269 PMCID: PMC5557243 SCOPUS ID: 2-s2.0-85020548304 06/13/2017       6 Citations
  • Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation. (Templin J, Atanackovic D, Hasche D, Radhakrishnan SV, Luetkens T) Oncotarget 2017 Jul 25;8(30):49253-49263 PMID: 28512269 PMCID: PMC5564765 SCOPUS ID: 2-s2.0-85025814243 05/18/2017       13 Citations
  • Current Strategies for the Immunotherapy of Multiple Myeloma. (Luetkens T, Yousef S, Radhakrishnan SV, Atanackovic D) Oncology (Williston Park) 2017 Jan 15;31(1):55-63 PMID: 28090624 SCOPUS ID: 2-s2.0-85050440905 01/17/2017    
  • Diagnosis and treatment of chronic graft‐versus‐host disease (Radhakrishnan SV, Couriel DR) Clinical Manual of Blood and Bone Marrow Transplantation 1 January 2017:334-347 SCOPUS ID: 2-s2.0-85218364311 01/01/2017    
  • Immunotherapies targeting CD38 in Multiple Myeloma. (Atanackovic D, Steinbach M, Radhakrishnan SV, Luetkens T) Oncoimmunology 2016;5(11):e1217374 PMID: 27999737 PMCID: PMC5139636 SCOPUS ID: 2-s2.0-84992493220 12/22/2016       36 Citations
  • Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. (Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T) Br J Haematol 2016 Mar;172(5):685-98 PMID: 26791002 SCOPUS ID: 2-s2.0-84958899793 01/23/2016       58 Citations
  • A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation patient population. (Radhakrishnan SV, Hildebrandt GC) Curr Hematol Malig Rep 2015 Mar;10(1):8-17 PMID: 25662904 SCOPUS ID: 2-s2.0-84925502984 02/11/2015       4 Citations
  • Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation. (Radhakrishnan SV, Palaniyandi S, Mueller G, Miklos S, Hager M, Spacenko E, Karlsson FJ, Huber E, Kittan NA, Hildebrandt GC) Biol Blood Marrow Transplant 2015 Jan;21(1):30-8 PMID: 25445642 SCOPUS ID: 2-s2.0-84927125235 12/03/2014       17 Citations
  • Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. (Schwab L, Goroncy L, Palaniyandi S, Gautam S, Triantafyllopoulou A, Mocsai A, Reichardt W, Karlsson FJ, Radhakrishnan SV, Hanke K, Schmitt-Graeff A, Freudenberg M, von Loewenich FD, Wolf P, Leonhardt F, Baxan N, Pfeifer D, Schmah O, Schönle A, Martin SF, Mertelsmann R, Duyster J, Finke J, Prinz M, Henneke P, Häcker H, Hildebrandt GC, Häcker G, Zeiser R) Nat Med 2014 Jun;20(6):648-54 PMID: 24836575 SCOPUS ID: 2-s2.0-84902203966 05/20/2014       250 Citations
  • Murine cytomegalovirus immediate-early 1 gene expression correlates with increased GVHD after allogeneic hematopoietic cell transplantation in recipients reactivating from latent infection. (Palaniyandi S, Radhakrishnan SV, Karlsson FJ, Stokes KY, Kittan N, Huber E, Hildebrandt GC) PLoS One 2013;8(4):e61841 PMID: 23596528 PMCID: PMC3626592 SCOPUS ID: 2-s2.0-84876195809 04/19/2013       11 Citations
    • Last update: 01/24/2026